Compass Pathways Reports Q3 2026 Financial Results and COMP360 Regulatory Update
Compass Pathways (CMPS) reported its third-quarter 2026 financial results, highlighting a significant increase in cash reserves to $444 million from $149.6 million at the end of 2025. The company reported a net loss of $9.8 million for the quarter, a substantial improvement over the $137.7 million loss recorded during the same period in 2025. This improvement was aided by a $40.8 million non-cash gain from warrant liability adjustments. On the regulatory front, the company is nearing a major milestone with the final rolling NDA submission for its COMP360 treatment for treatment-resistant depression (TRD) expected within two weeks. Utilizing a National Priority Voucher, Compass Pathways aims for an expedited FDA review of one to two months, targeting a commercial launch in the U.S. during the first half of 2027. Management expressed confidence in their cash runway, stating current funds should support operations into 2028.
Tickers: $CMPS
Topics: cash runway earnings report FDA submission financial results
Read the full article at Motley Fool
Part of the story DeFi Technologies Schedules Shareholder Call for Q3 2026 Financial Results (51 articles)